FDA Approved: GABAPENTIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Gabapentin from ScieGen Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Epilepsy
• Neuropathic Pain
• Postherpetic Neuralgia

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

SUPPL AP for GABAPENTIN (GABAPENTIN)